Design of new drugs for medullary thyroid carcinoma

Medullary thyroid carcinoma (MTC) is one of the common malignant endocrine tumors, which seriously affects human health. Although surgical resection offers a potentially curative therapeutic option to some MTC patients, most patients do not benefit from it due to the difficulty to access the tumors...

Full description

Bibliographic Details
Main Authors: Yanqing Li, Ziyu Luo, Xinxing Wang, Songtao Zhang, Hu Hei, Jianwu Qin
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-12-01
Series:Frontiers in Oncology
Subjects:
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2022.993725/full
_version_ 1797985226942578688
author Yanqing Li
Yanqing Li
Ziyu Luo
Ziyu Luo
Xinxing Wang
Songtao Zhang
Songtao Zhang
Hu Hei
Hu Hei
Jianwu Qin
Jianwu Qin
author_facet Yanqing Li
Yanqing Li
Ziyu Luo
Ziyu Luo
Xinxing Wang
Songtao Zhang
Songtao Zhang
Hu Hei
Hu Hei
Jianwu Qin
Jianwu Qin
author_sort Yanqing Li
collection DOAJ
description Medullary thyroid carcinoma (MTC) is one of the common malignant endocrine tumors, which seriously affects human health. Although surgical resection offers a potentially curative therapeutic option to some MTC patients, most patients do not benefit from it due to the difficulty to access the tumors and tumor metastasis. The survival rate of MTC patients has improved with the recent advances in the research, which has improved our understanding of the molecular mechanism underlying MTC and enabled the development and approval of novel targeted drugs. In this article, we reviewed the molecular mechanisms related to MTC progression and the principle for the design of molecular targeted drugs, and proposed some future directions for prospective studies exploring targeted drugs for MTC.
first_indexed 2024-04-11T07:15:02Z
format Article
id doaj.art-ea095d602b7a4f1d907297e30c6fe3b1
institution Directory Open Access Journal
issn 2234-943X
language English
last_indexed 2024-04-11T07:15:02Z
publishDate 2022-12-01
publisher Frontiers Media S.A.
record_format Article
series Frontiers in Oncology
spelling doaj.art-ea095d602b7a4f1d907297e30c6fe3b12022-12-22T04:38:02ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2022-12-011210.3389/fonc.2022.993725993725Design of new drugs for medullary thyroid carcinomaYanqing Li0Yanqing Li1Ziyu Luo2Ziyu Luo3Xinxing Wang4Songtao Zhang5Songtao Zhang6Hu Hei7Hu Hei8Jianwu Qin9Jianwu Qin10Department of Thyroid and Neck, The Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, ChinaThe Medical School of Zhengzhou University, Zhengzhou, ChinaDepartment of Thyroid and Neck, The Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, ChinaThe Medical School of Zhengzhou University, Zhengzhou, ChinaDepartment of Pain and Rehabilitation and Palliative Medicine, Henan Cancer Hospital, Zhengzhou, ChinaDepartment of Thyroid and Neck, The Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, ChinaThe Medical School of Zhengzhou University, Zhengzhou, ChinaDepartment of Thyroid and Neck, The Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, ChinaThe Medical School of Zhengzhou University, Zhengzhou, ChinaDepartment of Thyroid and Neck, The Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, ChinaThe Medical School of Zhengzhou University, Zhengzhou, ChinaMedullary thyroid carcinoma (MTC) is one of the common malignant endocrine tumors, which seriously affects human health. Although surgical resection offers a potentially curative therapeutic option to some MTC patients, most patients do not benefit from it due to the difficulty to access the tumors and tumor metastasis. The survival rate of MTC patients has improved with the recent advances in the research, which has improved our understanding of the molecular mechanism underlying MTC and enabled the development and approval of novel targeted drugs. In this article, we reviewed the molecular mechanisms related to MTC progression and the principle for the design of molecular targeted drugs, and proposed some future directions for prospective studies exploring targeted drugs for MTC.https://www.frontiersin.org/articles/10.3389/fonc.2022.993725/fullmedullary thyroid carcinomatargeted drugmolecular mechanismdesigned principleprogression
spellingShingle Yanqing Li
Yanqing Li
Ziyu Luo
Ziyu Luo
Xinxing Wang
Songtao Zhang
Songtao Zhang
Hu Hei
Hu Hei
Jianwu Qin
Jianwu Qin
Design of new drugs for medullary thyroid carcinoma
Frontiers in Oncology
medullary thyroid carcinoma
targeted drug
molecular mechanism
designed principle
progression
title Design of new drugs for medullary thyroid carcinoma
title_full Design of new drugs for medullary thyroid carcinoma
title_fullStr Design of new drugs for medullary thyroid carcinoma
title_full_unstemmed Design of new drugs for medullary thyroid carcinoma
title_short Design of new drugs for medullary thyroid carcinoma
title_sort design of new drugs for medullary thyroid carcinoma
topic medullary thyroid carcinoma
targeted drug
molecular mechanism
designed principle
progression
url https://www.frontiersin.org/articles/10.3389/fonc.2022.993725/full
work_keys_str_mv AT yanqingli designofnewdrugsformedullarythyroidcarcinoma
AT yanqingli designofnewdrugsformedullarythyroidcarcinoma
AT ziyuluo designofnewdrugsformedullarythyroidcarcinoma
AT ziyuluo designofnewdrugsformedullarythyroidcarcinoma
AT xinxingwang designofnewdrugsformedullarythyroidcarcinoma
AT songtaozhang designofnewdrugsformedullarythyroidcarcinoma
AT songtaozhang designofnewdrugsformedullarythyroidcarcinoma
AT huhei designofnewdrugsformedullarythyroidcarcinoma
AT huhei designofnewdrugsformedullarythyroidcarcinoma
AT jianwuqin designofnewdrugsformedullarythyroidcarcinoma
AT jianwuqin designofnewdrugsformedullarythyroidcarcinoma